You are here

  • Home
  • Archive
  • Volume 22, Issue 5
  • Routine invasive strategies compared with conservative strategies do not lower the all-cause mortality in patients with non-ST elevation myocardial infarction and unstable angina

Article Text

Article menu
Download PDFPDF
Commentary
Emergency care
Routine invasive strategies compared with conservative strategies do not lower the all-cause mortality in patients with non-ST elevation myocardial infarction and unstable angina
  1. Udho Thadani
  1. Department of Medicine, Cardiovascular Section, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA
  1. Correspondence to Dr Udho Thadani, Department of Medicine, Cardiovascular Section, University of Oklahoma Health Sciences Center, 800 Stanton Young Blvd, COM 5400, Oklahoma City, Oklahoma 73104, USA; Udho-Thadani{at}ouhsc.edu

https://doi.org/10.1136/ebmed-2016-110527

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Commentary on: Fanning JP, Nyong J, Scott IA, et al. Routine invasive strategies versus selective invasive strategies for unstable angina and non-ST elevation myocardial infarction in the stent era. Cochrane Database Syst Rev 2016:CD004815.

    Context

    Urgent coronary artery revascularisation with stents following an acute ST elevation myocardial infarction (MI) reduces mortality and the incidence of reinfarction. Current guidelines recommend the use of routine invasive strategies (RINVS) in patients with an acute non-ST elevation (NSTE) MI and in those with unstable angina (UA) with high-risk features. However, these guidelines are not necessarily evidence-based, and concern remains whether the RINVS is indeed superior to a selective invasive strategy (SINVS). This review and meta-analysis compares the benefits and harms associated with RINVS, in the stent era, with or without the use of glycoprotein (GP) IIb/IIIa receptor antagonists, with SINVS in patients with …

    View Full Text

    Footnotes

    • Competing interests None declared.

    • Provenance and peer review Commissioned; internally peer reviewed.